The US Pancreatic Cancer drugs market size is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Pancreatic cancer is one of the aggressive cancers that originate in the tissues of the pancreas and rapidly spreads to the nearby organs. The increasing incidence and prevalence of pancreatic cancer are expected to increase the demand for drugs, therapies, and treatment of patients. Moreover, the rising number of patients results in advancements in molecular biology and chemical drug formulation. Thus, a huge pool of patients who have pancreatic cancer is expected to increase the growth of the US pancreatic cancer therapy market over the forecast years.
Advancement of technology in therapeutic devices and expanding prevalence of cancer growth are the factors driving the market. The increasing pervasiveness of pancreatic cancer in developed nations due to the absence of therapeutic procedures for early-stage detection pushes the pancreatic cancer therapeutics market. The significant incidence of pancreatic cancer initiates germline mutations is levelling up the demand of the market. The growing demand for targeted therapy is another factor propelling the growth of the pancreatic cancer therapeutics market. Targeted therapy singles receptors present in the cancer cells and do not affect the body’s healthy peripheral cells, unlike the conventional therapeutics’ method like chemotherapy. The increasing demand for targeted therapy drives the pancreatic cancer therapeutics market.
Major Pancreatic Cancer Type
The exocrine pancreatic cancer segment held the largest share of the market, by type. The exocrine pancreatic cancer segment is expected to grow at the fastest rate during the coming years as this type of cancer is the most common and majorly occurring type and thus is expected to have massive patient pool over the forecast years.